Table 1. Patient characteristics.

Patient ID	Age (years)	Gender	Stage	EDSS	MS lesion type		Methyl-prednisolone		Medication other than methyl- prednisolone	Disease duration (months)
					Acute	Chronic	Prior to MRI	At the time of MRI	At the time of MRI
1	27	Female	RRMS	2		X			Interferon beta	15.05
2	42	Male	RRMS	2		X		X	None	0.30
3	20	Male	RRMS	0	X*				Fingolimod	10.02
4	18	Male	RRMS	2		X			Interferon beta	9.63
5	58	Male	RRMS	3		X			Glatiramer ac.	412.55
6	33	Male	RRMS	1.5	X	X			Glatiramer ac.	44.05
7	25	Male	RRMS	0	X*		X		None	5.55
8	50	Male	RRMS	0		X			Natalizumab	96.62
9	50	Female	RRMS	4	X*	X	X		None	66.06
10	49	Male	RRMS	1.5		X			Dimethyl fum.	231.67
11	47	Female	RRMS	4		X			Interferon beta	212.32
12	39	Female	RRMS	2	X		X		None	0.03
13	34	Female	RRMS	NI	X	X	X		NI	NI
14	52	Female	RRMS	3	X	X			Glatiramer ac.	101.08
15	48	Female	RRMS	2	X	X	X		None	0.03
16	50	Female	RRMS	5	X		X		None	0.53
17	50	Female	SPMS	5.5		X			Glatiramer ac.	103.84
18	25	Female	RRMS	1		X			Fingolimod	102.83
19	23	Female	RRMS	0		X			Fingolimod	30.09
20	40	Male	RRMS	3		X			Interferon beta	28.91
21	25	Female	RRMS	2	X	X	X		Interferon beta	34.76
22	43	Male	RRMS	2	X	X			Interferon beta	24.80
23	27	Female	RRMS	2	X*	X	X		None	4.07
24	45	Female	RRMS	4	X	X			Fingolimod	210.91
25	34	Female	RRMS	1	X	X			Interferon beta	43.36
26	37	Male	RRMS	2.5		X			Interferon beta	73.23
27	36	Male	RRMS	1	X	X			None	0.99
28	60	Male	RRMS	1.5		X			None	49.87
29	34	Male	RRMS	2	X	X	X		None	110.32

RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; *acute lesion of the spinal cord, no brain lesion; ac. = acetate; fum. = fumarate; NI = no information available.